Key result
Fifteen-year review details clinical experience and outcomes with lipid-lowering drugs in heterozygous familial hypercholesterolemia.
Answers are grounded in this paper and cite their sources.
A 15-year clinical history discussing the use of lipid-lowering drugs in patients with heterozygous familial hypercholesterolaemia.
Dear EditorHeterozygous familial hypercholesterolaemia (HeFH) is an autosomal dominant metabolic disorder characterised by impaired low-density lipoprotein receptor (LDLR) function, leading to redu...
No takes yet. Share an insight, caveat, or question.
Sbrana et al. (2026) studied this question. Lipid-lowering drugs for heterozygous familial hypercholesterolemia were evaluated over a 15-year clinical history.
Synapse has enriched 10 related papers. Consider them for comparative context: